The QUALMS in Action

The QUALMS has been incorporated into NHLBI's observational National Myelodysplastic Syndrome Natural History Study (expected n=2500).

The QUALMS is now being used in the MDS-CAN Registry.

The following are some protocols that feature the QUALMS:

• Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS

​

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients with Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) with an IDH1 Mutation (PyramIDH)

​

• A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants with International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

​

• Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

​

• Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL.

• Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome.

• Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients.

• Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).

• Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions.

• Lifestyle-modifying Interventions in Low-risk MDS Patients.

• Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS.

​

• Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease.

​​

• MDS-RIGHT: Providing the right care to the right patient with Mylelodysplastic Syndrome at the right time.